Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PIPE-791 for idiopathic pulmonary fibrosis
jRCT2061260085Phase 2Not yet recruiting
- Sponsor
- Contineum Therapeutics
- Start
- Dec 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of PIPE-791 in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Contineum Therapeutics. Primary endpoint: Change in FVC from baseline to Week 26. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
PIPE-791
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2061260085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061260085.